| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e2e13b73e8528b3bbfad4a0e5619d52 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2503-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2016-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e8d48ac4ab18d64d0e89c66a8dc8792 |
| publicationDate |
2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10415094-B2 |
| titleOfInvention |
Risk stratification method for a patient having a polymorphism |
| abstract |
A risk stratification method for a patient in a disease state and specifically patients presenting a tumor, includes determining if the patient is a homozygote or heterozygote and further determining the allelic expression for the patient, CC, T/C, or C/T. For patients having the cytosine methylated, they have a TIC allelic expression and patients without a methylated cytosine have a C/T allelic expression. A patient with a TT allelic expression is classified as a highest risk patient, a patient with a TIC allelic expression is classified as a second highest risk patient, a patient with a C/T allelic expression is classified as a third highest risk patients and a patient with a CC allelic expression is classified as a lowest risk patient. The risk stratification method may further include identification of an abnormal expression or mutation/function of a gene product produced by CTCF binding site 6. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11408035-B2 |
| priorityDate |
2016-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |